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Abstract
The treatment of tuberculosis (TB) poses a major challenge as frontline therapeutic agents become increasingly ineffective with
the emergence and spread of drug-resistant strains of Mycobacterium tuberculosis (Mtb). To combat this global health problem, new
antitubercular agents with novel modes of action are needed. We have screened a close family of 17 organometallic half-sandwich
Os(II) complexes [(arene)Os(phenyl-azo/imino-pyridine)(Cl/I)]+Y– containing various arenes (p-cymene, biphenyl, or terphenyl), and
NMe2, F, Cl, or Br phenyl or pyridyl substituents, for activity towards Mtb in comparison with normal human lung cells (MRC5). In
general, complexes with a monodentate iodido ligand were more potent than chlorido complexes, and the five most potent iodido
complexes (MIC 1.25–2.5 μM) have an electron-donating Me2N or OH substituent on the phenyl ring. As expected, the counter anion
Y (PF6–, Cl–, I–) had little effect on the activity. The pattern of potency of the complexes towards Mtb is similar to that towards human
cells, perhaps because in both cases intracellular thiols are likely to be involved in their activation and their redox mechanism of
action. The most active complex against Mtb is the p-cymene Os(II) NMe2-phenyl-azopyridine iodido complex (2), a relatively inert
complex that also exhibits potent activity towards cancer cells. The uptake of Os from complex 2 by Mtb is rapid and peaks after 6 h,
with temperature-dependence studies suggesting a major role for active transport.
Significance to Metallomics
Antimicrobial resistance is a global health problem. New advances are urgently needed in the discovery of new antibiotics with novel
mechanisms of action. Half-sandwich organometallic complexes offer a versatile platform for drug design. We show that with an
appropriate choice of the arene, an N,N-chelated ligand, and monodentate ligand, half-sandwich organo–osmium(II) complexes can
exhibit potent activity towardsMycobacterium tuberculosis (Mtb), the leading cause of death from a single infectious agent. The patterns
of activity of the 17 azo- and imino-pyridine complexes studied here towards Mtb and normal lung cells suggest a common redox
mechanism of action involving intracellular thiols.
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Graphical abstract
Organo-osmiumhalf-sandwich complexes showhigh potency towardsMycobacterium tuberculosis (Mtb).Overlay of the crystallographic
structure of osmium complex 2 and Mtb cells with a graph showing cellular accumulation of osmium in Mtb.
Introduction
Mycobacterium tuberculosis (Mtb), the causative agent of tuberculo-
sis (TB), is a major global health challenge. TB is now the leading
cause of death from a single infectious agent, killing more peo-
ple than HIV and malaria combined.1 In 2019, ∼1.4 million peo-
ple died from this devastating disease and over 10 million new TB
cases were reported.1 Drug-sensitive TB is curable; however, the
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complicated 6–9 months treatment regime introduced into the
clinic decades ago has gradually become less effective as drug-
resistant TB strains have emerged. Treatment of multi-drug resis-
tant (MDR) TB, characterized by resistance to both isoniazid and
rifampicin, and extensively drug-resistant (XDR) TB, characterized
by resistance to isoniazid, rifampicin, a fluoroquinolone, and one
of the injectable second-line drugs, further complicates therapy
and often has poor treatment outcomes.2 The escalation of MDR
TB and XDR TB has, in turn, led to totally drug-resistant strains
of TB and in these cases there are no effective therapeutic agents
for successful treatment.3 Therefore, there is an urgent need to
develop new TB drugs that have novel mechanisms of action to
reduce the TB burden and tackle this global health crisis.
An analysis of compounds screened for antimicrobial activ-
ity by the Community for Open Antimicrobial Drug Discovery
has shown that metal complexes have a significantly higher
hit rate against critical bacterial and fungal pathogens than or-
ganic compounds.4 Recent studies on the antimicrobial activity
of organometallic complexes (i.e. metal coordination complexes
containing metal–carbon bonds) show that they are potentially
an encouraging source of novel antibiotics, including complexes
of Re, Fe, Ru, Os, Ir, and Au. The C-bound ligands include arenes,
cyclopentadienyls, CO, CN–, and deprotonated phenyls (often cy-
clometallated ligands).5–12
Half-sandwich ‘piano-stool’ complexes containing a π-bonded
neutral arene or negatively charged cyclopentadienyl ligand effec-
tively occupying three coordination sites, and three other donors
giving pseudooctahedral geometry (or alternatively described as
pseudotetrahedral) are one such class.13 Osmium(II)- and Ru(II)-
arene complexes, as well as Rh(III)- and Ir(III)-cyclopentadienyl
(Cp) complexes have been widely investigated as potential an-
ticancer agents.14–16 More recently, the antimicrobial activity
of Ir(III), Rh(III), and Ru(II) complexes has been reported, as
both 18-electron (6-coordinate) and 16-electron (5-coordinate)
half-sandwich complexes.13,17 The lipophilicity of the η6/η5-
coordinated arene/Cp ring and the complex can be modulated by
extension (e.g. phenylation) of the ring, whilst the monodentate
and bidentate ligands allow further structural and electronic con-
trol of reactivity, including the incorporation of bio-activemoieties
and fine-tuning of the redox chemistry of the complex. Both the
intact complex and the individual ligands can all play a role in the
biological mechanism of action. Such mechanisms can therefore
be multi-targeting, perhaps an advantage for overcoming resis-
tance. Surprisingly, although compounds of Os(II) have recently
found recognition as potential anticancer agents,18–20 their appli-
cation to the treatment of tuberculosis has not yet been explored.
Os(II) arene azopyridine and iminopyridine complexes have been
shown to be highly potent towards cancer cells, with some selec-
tivity for cancer cells versus normal human cells.21–23
In this work, we investigate the activity of a family of struc-
turally related osmium–arene complexes againstMtb and normal
lung cells. We also study the time dependence and temperature
dependence of intracellular osmium accumulation inMtb for one
of the most potent complexes.
Results and discussion
Antibacterial potency
Minimum inhibitory concentrations (MICs) against Mtb were de-
termined for a series of 17 structurally related ‘piano-stool’
osmium(II) p-cymene (para-cymene) or biphenyl arene, azo- and
imino-pyridine complexes containing either chloride or iodide as
a monodentate ligand (Fig. 1). The MIC testing was carried out in
Fig. 1 Generic structure of Os(II) arene ‘piano-stool’ complexes studied
in this work.
Middlebrook 7H9 broth supplemented with 0.2% glycerol, 0.05%
Tween 80, and 10% albumin–dextrose–catalase (ADC).
Previous work has shown that iodido complexes in this series
are usually relatively inert, e.g. towards aquation, in comparison
with chlorido complexes. It is notable that these small changes
in the ligands have a significant effect on the activities, ranging
across two orders of magnitude (1.25–125 μM, Table 1).
For this family of osmium complexes, biphenyl (R1) complexes
often exhibit higher activity towards cancer cell lines than their
p-cymene analogues.24–26 However, osmium–biphenyl (R1) com-
plexes appear less potent towards Mtb than their p-cymene ana-
logues, e.g.MIC of 31.25 μM for 3 compared with 5 μM for 1. The R1
arene substituent can increase lipophilicity and promote uptake
of the complex into cells, which is particularly important for im-
port into Mtb as it has a complicated lipid-rich cell envelope that
is highly impenetrable to most antibiotics.27
Complexes with an iodido monodentate ligand (X) were be-
tween 2 and 12.5× more active against Mtb than their chlorido
counterparts, c.f. 1 vs 2, 3 vs 4, 5 vs 6, 9 vs 10, and 16 vs 17, a trend
commonly observed for mammalian cancer cell lines studies.24,26
Chemical and radiotracer studies using 131I (β−/γ emitter, t1/2 8.02
days) suggest that the iodido azopyridine complexes, which are
relatively inert towards ligand exchange reactions, are activated
inside human carcinoma cells,28 through attack on the azo bond
by the thiol of glutathione (GSH), which is abundant (millimolar
concentrations) in cells. Initially, this leads to release of the iodide
ligand and formation of the more reactive chlorido and hydroxido
adducts in cells. Then, thiolato (GS) and sulfenato (GSO) adducts
can form, which can react with hydrogen peroxide, generating re-
active oxygen species (ROS) inside cells.28,29 Thiols may also be
involved in the intracellular activation of these potent osmium–
arene complexes in Mtb cells. Whilst Mtb lacks the glutathione
system, there are a number of thiols present at similar levels to
those of GSH in mammalian cells: ergothioneine (ERG), mycoth-
iol (MSH), and γ -glutamylcysteine (GGC).30,31 They probably fulfil
similar roles: maintaining the redox balance and counteracting
ROS, protecting against oxidative stress (ROS), and are likely to in-
teract with the osmium complexes as GSH does in mammalian
cells.32
Introduction of an R3 = NMe2 substituent onto the phenyl ring
of the azopyridine bidentate ligand (complexes 1 and 2) enhances
activity againstMtb, compared with unsubstituted (R3 = H) coun-
terparts, complexes 9 and 10, respectively. This group is known
to enhance potency and selectivity in human cell lines,22,23,28 and
also appears to contribute to the overall antimycobacterial activ-
ity. Imino complexes 5 and 6 were less potent towards Mtb than
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R1 R2 R3 R4 X Y– H37Rv MRC5
1 p-cym N 3-NMe2 H Cl PF6 5 7.1 ± 0.2
2 p-cym N 3-NMe2 H I PF6 1.25 0.89 ± 0.01
3 biphenyl N 3-NMe2 H Cl PF6 31.25 16.9 ± 0.1
4 biphenyl N 3-NMe2 H I PF6 2.5 0.42 ± 0.03
5 p-cym CH 3-NMe2 H Cl PF6 31.25 7.6 ± 0.9
6 p-cym CH 3-NMe2 H I PF6 7.81 13 ± 2
7 p-cym N 3-NMe2 H I Cl 1.25 0.68 ± 0.03
8 p-cym N 3-NMe2 H I I 1.25 0.42 ± 0.01
9 p-cym N H H Cl PF6 15.6 15 ± 2
10 p-cym N H H I PF6 5 0.79 ± 0.06
11 p-cym N H 5-Br Cl PF6 125 18 ± 1
12 p-cym N H 5-F I PF6 15.6 9.1 ± 0.6
13 biphenyl N H 5-F I PF6 62.5 5.2 ± 0.7
14 p-cym N H 5-Cl I PF6 62.5 16 ± 2
15 biphenyl CH 3-OH H I PF6 5 13.5 ± 0.9
16 p-cym N 3-OH Br Cl PF6 10 0.08 ± 0.01
17 p-cym N 3-OH Br I PF6 2.5 0.62 ± 0.01
Rifampicin N/A N/A N/A N/A N/A N/A 0.38–0.76 n.d.
Cisplatin N/A N/A N/A N/A N/A N/A n.d. 13.5 ± 0.9
aMIC determined using resazurin, after 7-day exposure to the Os(II) complex (results represent three independent biological repeats); the medium used was Mid-
dlebrook 7H9 broth supplemented with 0.2% glycerol, 0.05% Tween 80, and 10% ADC. MBC values were obtained for 1 (12.5 μM), 2 (6.25 μM), and 4 (6.25 μM).
bIC50 determined using the SRB assay after 24 h drug exposure and 72 h recovery time in drug-free medium (results represent three independent biological repeats).
N/A = not applicable; n.d. = not determined.
the nature of the azo bond is important. It seems likely that redox
reactions involving the azo bond may be involved not only in the
mechanism of cytotoxicity towards human cancer cells but also
towards Mtb.33
Generally, introduction of halide (electron-withdrawing) moi-
eties at the R4 position was detrimental to both mammalian
and mycobacterial potencies (compounds 11–14), with potency
inversely correlated with the size of the halide substituent: 11
(R4 = Br, least active) < 14 (R4 = Cl) < 12 (R4 = F, most active)
(Table 1). Conversely, and although directly comparable com-
plexes were not available, the introduction of Br at the R4 position
in R3 = 3-OH complexes (16 and 17) did not appear to affect signif-
icantly the potency in either mammalian or mycobacterial cells.
The apparent inertness of this site towards substitution reactions
suggests that itmay be suitable for further investigation (e.g. poly-
mer conjugation as part of a future drug-delivery strategy).
Complex 2 [Os(AzPy-NMe2)I(p-cymene)]PF6 (AzPy: 2-
phenylazopyridine) has previously shown promise as a candidate
anticancer drug, with selectivity for cancer cells over healthy
cells.34 In our current work, this compound also possesses high
antitubercular activity, with an MIC potency of 1.25 μM, which
is comparable with MIC values of ∼1–9 μM for current clinical
TB drugs isoniazid (∼1 μM), ethambutol (∼5 μM), capreomycin
(∼3 μM), and streptomycin (∼9 μM). However, complex 2 has a
lack of selectivity towards normal human cells compared with
the bacteria (Table 1). We have recently reported the procedure
for exchange of the counter anion in these complexes, using
anion exchange resin and column chromatography.35 As might be
expected, since the complexes are salts, variation in the counter
anion for complex 2 from X– = PF6–, to Cl– (complex 7), or I–
(complex 8) had little effect on the antimicrobial activity of the
compound (1.25 μM), although this change in halide counter ion
has a significant effect on the aqueous solubility of the complexes
(7 >> 8 > 2).
The minimal bactericidal concentrations (MBCs) were deter-
mined for compound 1 (12.5 μM), compound 2 (6.25 μM), and com-
pound 4 (6.25 μM). Compared with the determined MIC values
(Table 1), there is good correlation with the MBCs for compounds
1 and 4, indicating that these compounds are bactericidal against
actively growing Mtb, whereas compound 2 displayed an MBC 5×
greater than the corresponding MIC value.
Comparable activity trends in MIC and IC50 (half-maximal in-
hibitory concentrations) are observed for Mtb and MRC5 normal
human lung cell lines (Table 1; Fig. 2). Iodido complexes are more
active than their chlorido counterparts, and azo ligands impart
greater antiproliferative activity than their imino analogues. In
general, there is little selectivity for Mtb versus the human cells
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Fig. 2 Comparison of the cytotoxicity of complexes 1–17 towards Mtb
(MIC μM values) and normal MRC5 human lung fibroblasts (IC50 μM
values). In general, high activity against Mtb is paralleled by high activity
towards the human cells, with low selectivity for Mtb cells observed. The
results represent three biological repeats. Points are labelled with
complex numbers according to Table 1, except for highly active
complexes 4, 7, 8, 10, and 17, which are clustered near the origin.
complexes 6, 9, and 15 do show higher relative potency for Mtb
compared with the MRC5 cells, suggesting that these complexes
could act as leads for further optimization.
Accumulation of osmium in cells
Mtb cells were exposed to complex 2 for 24 h at a concentration
of 0.625 μM (0.5 × MIC), with time-dependent sampling from the
culture either with or without shaking. Shaking was found to af-
fect significantly the Os accumulation profile (Fig. 3A), increasing
the initial rate of Os accumulation, leading to peak accumulation
after 6 h. In contrast, Mtb cells that were cultured without shak-
ing accumulated Os at a much slower rate, with an accumulation
maximum being reached after ∼17 h.
For Mtb cells incubated with shaking, the intracellular concen-
tration of Os decreased after 6 h, and after 5 days was negligible,
suggesting an active contribution from efflux mechanisms, irre-
spective of the extracellular Os concentration gradient (Fig. 3B).
Mtb cellular osmium accumulation is a result of two processes: in-
flux and efflux, and these data suggest that, after 6 h, either: (i) the
rate osmium of influx must decrease by an unknown mechanism
(to a rate less than the rate of efflux), or (ii) the rate of osmium
efflux must increase (and surpass the rate of influx). Similar ac-
cumulation profiles have been observed and modelled for mam-
malian cancer cells.36 These models demonstrated that, in mam-
malian cells, the reduction in intracellular Os is a consequence of
reduced osmium influx, rather than increased efflux, after reach-
ing a critical intracellular concentration threshold.36
The temperature dependence of osmium accumulation was
next investigated by incubating Mtb at 277 K with complex 2 in
a time-dependent manner in static cultures. These data demon-
strate that Os accumulation depends on contributions from pas-
sive and active transport mechanisms. Active transport requires
energy; therefore, at lower temperatures active transport would
be diminished. Osmium accumulation at 277 K suggests passive
diffusion of the complex across the lipid envelope (Fig. 4). Previous
studies have demonstrated that the intracellular Os accumula-
tion also decreased at lower temperature in mammalian cells: by
4-fold at 296 K, and by 31-fold at 277 K, compared with the intra-
cellular concentration determined at 310 K.36 Since osmium from
complex 2 was still accumulated at low temperature (in both Mtb
and mammalian cells), this suggests that its uptake is partially
passive and not entirely energy-dependent.
Conclusions
The well-known compound OsO4, a strong oxidant used as a stain
for cells, and intriguingly for treatment of synovitis of the knee,37
contains osmium in oxidation state +8, in contrast to the Os(II)
complexes used in the present work. The chemical and biologi-
cal properties of osmium complexes depend not only on the ox-
idation state of osmium but also on the nature of the coordi-
nated ligands and the geometry of the complex. This is clear from
the anti-Mtb activity of complexes 1–17 that ranges from 1.25 to
Fig. 3 Time-dependent accumulation of Os from complex 2 by Mtb H37Rv cells (determined by ICP-MS), normalized to phosphorus content. Cells were
treated using 0.5× MIC (0.625 μM) concentrations of complex 2 and incubated at 310 K. (A) During incubation time, not shaking the culture ( ) was
found to decrease the rate of osmium accumulation over the first 6 h of incubation, relative to the comparative experiment with shaking (●); (B) with
shaking (●), osmium accumulation reaches a peak after 6 h of exposure; however, after 5 days, the intracellular osmium concentration is negligible.
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Fig. 4 Temperature-dependent accumulation of Os (ICP-MS) by Mtb,
normalized to phosphorus content (ICP-OES). Cells were treated using
0.5× MIC (0.625 μM) of complex 2 and incubated at 277 K without
shaking ( ) and are shown compared with data obtained at 310 K
without shaking ( ). Full numerical data can be found in Table S2. Error
bars are ±SD.
125 μM. Moreover, these complexes form a close family, with the
same half-sandwich structures and only small variations in the
ligands. For changes in the N,N-chelated ligand, the activity in-
creases for azo > imino, and for the monodentate ligand I > Cl.
The 4–6× increase in activity conferred by the presence of the
NMe2 group on the phenyl ring of the N,N-chelated ligand is also
notable. This activity pattern is paralleled in activity towards hu-
man cancer cells.24–26 Although complex 15 shows selectivity for
Mtb versus normal human cells by a factor of 3 (Fig. 2), the se-
lectivity needs to be improved for clinical development. However,
selectivity for microbes versus human cells in culture, although a
desirable initial goal, may not translate to selectivity in the body
where additional metabolic processes can occur in various organs
and tissues (depending on the route of administration). Selectiv-
ity might be improved by conjugation of complexes to targeting
vectors for Mtb to the ligands, or by formulation in nanoparticles
that introduce selective delivery.
Compared with cancer cells, little work has been done so far
on understanding intracellular reactions of antimicrobial metal-
lodrugs. In the present case, it seems likely that inert organo–
osmium complexes are activated inMtb by reaction with intracel-
lular thiols, as they are in mammalian cells,28 generating ROS.38
γ -Glutamylcysteine, a precursor to GSH in mammalian cells, in
Mtb is likely to react similarly to GSH, and it will be interesting to
compare with ergothioneine and mycothiol.
Current widely used transition metal drugs in clinical use in-
clude the platinum anticancer drug cisplatin and antimicrobial
silver compounds such as silver sulfadiazine.39 The attraction
of such metal compounds as drugs relates partly to their novel
mechanisms of action compared with organic drugs.4 Organo-
osmium complexes are therefore worthy of further investigation.
Experimental Materials
Osmium(II) azopyridine and osmium(II) iminopyridine complexes
have been previously reported and fully characterized. Changes
in the counter anions (e.g. conversion of PF6– salt 2 to Cl– salt 7)
were carried out by ion-exchange chromatography as described
recently.35
DMEM culture medium was purchased from Scientific Labo-
ratory supplies. Foetal calf serum (batch 70428) was purchased
from Lab Tech International. Osmium trichloride was received
from Heraeus GmbH. Plasticware for biological experiments was
purchased from Greiner Bio-One. Ultrapure nitric acid (72% v/v)
was freshly distilled before use.All water used in experiments was
Type I Milli-Q (doubly deionized) water. ICP standards for Os were
purchased from Inorganic Ventures. All other reagents were pur-
chased from Sigma Aldrich (Merck) and used as received, unless
indicated otherwise.
Synthesis of L1
p-Benzoquinone (316.0 mg, 2.93 mmol) was dissolved in deionized
water (50 mL) and perchloric acid (70% v/v, 2.6 mL) was added. A
solution of 5-bromo-2-hydrazinopyridine (500.0 mg, 2.66 mmol)
in MeOH (10 mL) was added dropwise to the stirring mixture.
The mixture turned red-brown and was stirred for 18 h at am-
bient temperature. The pH was neutralized with the dropwise ad-
dition of aqueous sodium hydroxide (6 M). The product was ex-
tracted with ethyl acetate (3 × 50 mL) and washed with water
(3 × 50 mL). The mixture was concentrated under reduced pres-
sure and placed in a freezer (253 K) overnight. The resulting brown
precipitate was collected via vacuum filtration and washed with
ice-cold EtOH (2 × 1 mL) and Et2O (2 × 5 mL). Yield: 495.5 mg
(67%). 1H NMR (400 MHz, CD3OD): δ 8.73 (d, 1H, J = 2.4 Hz), 8.19
(dd, 1H, J = 8.6, 2.4 Hz), 7.93–7.92 (m, 2H), 7.76 (d, 1H, J = 8.6 Hz),
6.96–6.94 (m, 2H). ESI-MS calculated for C11H9BrN3O+: m/z 278.0.
Found: 277.9. CHN analysis: Found: C, 47.28%; H, 2.80%; N, 14.82%.
Calculated for C11H8BrN3O: C, 47.51%; H, 2.90%; N, 15.11%.
Synthesis of complex 16
[Os(η6-p-cym)Cl2]2 (50.0 mg, 63.2 μmol) was dissolved in EtOH
(10 mL), and a solution of 5-Br-AzPy-OH (L1, 36.9 mg, 132.8 μmol)
in EtOH (5 mL) was added dropwise. The mixture was stirred
for 18 h at ambient temperature and then filtered through
glass microfibre to remove a black precipitate, and NH4PF6
(103.1 mg, 0.63 mmol) was added. The mixture was concen-
trated under reduced pressure to ∼3 mL and placed in a
freezer (253 K) overnight. A dark crystalline precipitate was
collected via vacuum filtration and washed with ice-cold EtOH (2
× 1 mL) and Et2O (2 × 5 mL) and dried overnight in a vacuum des-
iccator. Yield: 89.6 mg (91%). 1H NMR (400 MHz, (CD3)2CO): δ 9.66
(d, 1H, J = 2.1 Hz), 8.75 (d, 1H, J = 8.7 Hz), 8.56 (dd, 1H, J = 8.7,
2.1 Hz), 8.15–8.11 (m, 2H), 7.15–7.11 (m, 2H), 6.82–6.81 (m, 1H),
6.53–6.52 (m, 1H), 6.40–6.35 (m, 2H), 2.47 (sept., 1H, J = 6.9 Hz),
2.43 (s, 3H), 0.97 (d, 3H, J = 6.9 Hz), and 0.91 (d, 3H, J = 6.9 Hz).
ESI-MS calculated for C21H22BrClN3OOs+: m/z 638.0. Found: 637.9.
CHN analysis: Found: C, 31.87%; H, 2.70%; N, 5.16%. Calculated for
C21H22BrClF6N3OOsP: C, 32.21%; H, 2.83%; N, 5.37%. HPLC purity
98.3%.
Synthesis of complex 17
[Os(η6-p-cymene)I2]2 (100.0 mg, 86.5 μmol) was dissolved in EtOH
(10 mL), and a solution of 5-Br-AzPy-OH (L1, 50.5 mg, 181.6 μmol)
in EtOH (5 mL) was added dropwise. The mixture was stirred
for 18 h at ambient temperature and then filtered through glass
microfibre to remove a black precipitate, and NH4PF6 (140.9 mg,
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duced pressure to ∼3mL and placed in a freezer (253 K) overnight.
A dark crystalline precipitate was collected via vacuum filtration
and washed with ice-cold EtOH (2 × 1 mL) and Et2O (2 × 5 mL)
and dried overnight in a vacuum desiccator. Yield: 76.7 mg (51%).
1H NMR (400 MHz, CD3OD): δ 9.10–9.09 (m, 1H), 8.12–8.08 (m, 2H),
8.02–8.01 (m, 2H), 6.43–6.39 (m, 2H), 7.15–7.11 (m, 2H), 6.20–6.19
(m, 1H), 6.07–6.06 (m, 1H), 6.03–6.02 (m, 1H), 5.97–5.96 (m, 1H), 2.73
(s, 3H), 2.39 (sept., 1H, J = 6.9 Hz), 0.97 (d, 3H, J = 6.9 Hz), and 0.89
(d, 3H, J = 6.9 Hz). ESI-MS calculated for C21H22BrIN3OOs+: m/z
730.0. Found: 729.8. CHN analysis: Found: C, 28.62%; H, 2.63%; N,
4.73%. Calculated for C21H22BrF6IN3OOsP: C, 28.85%; H, 2.54%; N,
4.81%. HPLC purity 99.7%.
Bacterial strains and culture conditions
Mtb H37Rv was routinely grown at 37°C in Middlebrook 7H9 broth
(BD Difco, Oxford, UK) supplemented with 0.2% glycerol, 0.05%
Tween 80, and 10% ADC or on Middlebrook 7H10 plates supple-
mented with 10% glycerol and 10% oleic acid–albumin–dextrose–
catalase (OADC). Mtb was cultured within a containment level 3
(CL3) facility. Mtb samples were removed from the CL3 contain-
ment only after validation thatMtbwas killed following nitric acid
treatment.
Determination of MICs against Mtb
The MIC of all compounds was determined using the resazurin
microtitre assay, as described previously.40 Compounds were dis-
solved in dimethylsulfoxide (DMSO) and then diluted so that the
final concentration in themedia did not exceed 2% v/v.MtbH37Rv
was grown to mid-log phase [optical density at 600 nm (OD600)
of 0.6] and the inoculum was standardized to 1 × 106 colony-
forming units (CFUs)/mL before addition to a prepared 96-well flat
bottom microtitre plate with 2-fold serial dilutions of each com-
pound in media. Control experiments in which either no drug, or
rifampicin as an antibiotic control were also included on eachmi-
crotitre plate. The plates were incubated for 7 days at 310 K be-
fore the addition of 25 μL resazurin [one tablet of resazurin (VWR)
dissolved in 30 mL of sterile phosphate buffered saline (PBS). Fol-
lowing a further incubation for 24 h at 310 K, the plates were as-
sessed for colour development. The MIC values were determined
as the lowest concentration of drug that prevented the turnover
of resazurin from blue (no bacterial growth) to resorufin, pink
(bacterial growth). The results represent three independent bio-
logical repeats.
Determination of minimum bactericidal
concentrations against Mtb
The minimum bactericidal activity (MBC) was determined by set-
ting up a microtitre plate as performed for the MIC determina-
tion. Instead of adding resazurin, each well from the microtitre
plate was plated on to solid 7H10 medium and the CFUs were de-
termined after incubation at 37°C. The lowest concentration at
which no CFUs were counted was taken as the MBC. The MBCs
were carried out with three independent experimental repeats.
Os uptake experiments in Mtb
Mtb H37Rv was grown to an OD600 of 0.5 and then either com-
pound 2 (final concentration of 625 nM) or water was added. The
cultures were incubated at either 277 or 310 K over 24 h or 7 days.
At each time point,Mtb culture (1.5 mL) was removed, centrifuged
(10 min, 15 871 × g), the supernatant removed, and the pellet
washed three times with Tris-buffered-saline containing 0.05%
Tween 80 (TBST). The pellet was resuspended in 72% v/v nitric acid
(200 μL), heated to 353 K for 16 h, cooled to room temperature, and
diluted withMilli-Q water containing 100mg L–1 ascorbic acid and
10mM thiourea (3.8 mL). The results represent three independent
experimental repeats.
Human cell line maintenance
MRC5 (human foetal lung fibroblast) cell lines were obtained
from Public Health England (mycoplasma-free status confirmed
at six-monthly intervals by internal and external screening). They
were thawed upon receipt and the supernatant removed after
centrifugation (1000 rpm, 5 min). Cells were re-suspended in
DMEM culturemedium (supplementedwith 10% v/v FCS, 1% peni-
cillin/streptomycin, and 1% l-glutamine) and grown as adher-
ent monolayers at 310 K in a 5% CO2 humidified atmosphere.
Cells were passaged using trypsin/EDTA after reaching ∼90%
confluence. Trypsin activity was quenched by addition of excess
medium, and the single-cell suspension passaged twice weekly.
MRC5 fibroblasts were discarded after five passages.
Determination of antiproliferative activities
against human cell line
Briefly, 5 × 103 cells (MRC5) were seeded in a 96-well plate using
0.15 mL of culture medium. After 48 h pre-incubation at 310 K,
the supernatant was removed and cells exposed to six concentra-
tions (0–100 μM) of osmium complex, for which exact concentra-
tions were determined using ICP-OES (calibration standards for
Os freshly prepared in 3.6% v/v nitric acid containing 100 mg L–1
ascorbic acid and 10mM thiourea). DMSO was used to aid solubil-
ity of Os complexes, but never exceeded 0.5% v/v in the final cul-
ture medium. Cells were exposed to Os complexes for 24 h, and
then washed with PBS and allowed 72 h recovery time in drug-
free medium. Cell viability was determined using the sulforho-
damine B (SRB) assay. Cells were fixed using 50 μL of 50% TCA,
incubated at 277 K for 1 h, and then stained using SRB dye (0.4%
dye in 1% acetic acid). After 30 min, excess dye was removed by
acetic acid washing, and then the stain liberated using Tris base
(10 mM, pH 10.5). Absorbance was measured using a Thermo Sci-
entific Multiskan FC microplate reader fitted with a 492-nm filter.
Data were processed using Microsoft Excel and are reported as
percentage survival relative to the untreated control. Sigmoidal
dose/response curves were fitted using Origin 2016 to determine
IC50. Data were acquired as duplicate of triplicate experiments,
with a positive control of cisplatin (CDDP).
Quantification of cellular Os and P
Cell pellets were obtained and subjected to digestion using 200
μL of 72% v/v nitric acid. After 24 h incubation at 353 K, samples
were diluted using 3800 μL Milli-Q water containing 100 mg L–1
ascorbic acid and 10 mM thiourea to stabilize Os in nitric acid so-
lution. Samples were analysed using an Agilent Technologies 7900
Series ICP-MS (inductively coupled plasma-mass spectrometry) in
He gas mode. Calibration standards (0–1000 ppb) for 189Os and 31P
were freshly prepared in 3.6% v/v nitric acid containing 100 mg
L–1 ascorbic acid and 10 mM thiourea, and all samples analysed
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normalized to phosphorus content (μg Os/mg P) and standard de-
viations are reported.
Supplementary material
Supplementary data are available at Metallomics online.
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